Press Release Mar 07 2023
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Lenalidomide Capsules in two dosages. These capsules are intended for treating various cancers and certain blood disorders, and will soon be launched in the US market. The manufacturing will take place at Zydus's facility in Ahmedabad, India. This approval adds to Zydus's growing portfolio, which now includes a significant number of approvals since the filing process began.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Mar 03 2023
- Press Release Mar 02 2023
- Press Release Feb 28 2023
- Press Release Feb 24 2023
- Press Release Feb 20 2023
Later from Zydus Lifesciences
- Press Release Mar 09 2023
- Zydus Lifesciences Limited Press Release Mar 15 2023
- Press Release Mar 21 2023
- Press Release Mar 24 2023
- Press Release Mar 25 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences